60703_S134
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.430
- FATTY_ACID_METABOLISM+0.330
- COAGULATION+0.310
- MYOGENESIS+0.280
- OXIDATIVE_PHOSPHORYLATION+0.280
- XENOBIOTIC_METABOLISM+0.270
- KRAS_SIGNALING_DN+0.260
- ADIPOGENESIS+0.210
- ANDROGEN_RESPONSE+0.210
- PEROXISOME+0.210
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.540
- G2M_CHECKPOINT-0.510
- E2F_TARGETS-0.500
- MITOTIC_SPINDLE-0.450
- MYC_TARGETS_V2-0.430
- INTERFERON_GAMMA_RESPONSE-0.380
- NOTCH_SIGNALING-0.340
- PI3K_AKT_MTOR_SIGNALING-0.320
- MYC_TARGETS_V1-0.270
- WNT_BETA_CATENIN_SIGNALING-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD011_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.847 |
| 2 | SRR8518242 | — | F | 0.810 |
| 3 | SRR8613737 | — | F | 0.805 |
| 4 | TCGA-73-4677-01A-01R-1206-07 | — | cohortA2 | 0.803 |
| 5 | TCGA-A7-A0DB-01A-11R-A00Z-07 | — | A | 0.783 |
| 6 | SRR8518146 | — | F | 0.781 |
| 7 | SRR8518177 | — | F | 0.773 |
| 8 | SRR1516093 | — | — | 0.766 |
| 9 | SRR8518290 | — | F | 0.761 |
| 10 | TCGA-H4-A2HO-01A-11R-A180-07 | — | — | 0.760 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.430 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| PEROXISOME | 0.210 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.130 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.120 | Inavolisib | — uncovered |